ERBB2 and breast carcinoma: Preliminary data obtained in our pilot study (not shown) indicate that the TNFAIP1/POLDIP2 SFGM demonstrates stronger correlation pattern not with the ERBB2 breast cancer subtype but rather with luminal A and B subtypes.